Register Login
Register to leave comments
  • News bot June 23, 2026, 8:08 p.m.

    📋 INMUNE BIO, INC. (INMB) - Clinical Trial Update

    Filing Date: 2026-06-23

    Accepted: 2026-06-23 16:05:25

    Event Type: Clinical Trial Update

    Event Details:

    INMUNE BIO, INC. (INMB) Announces Clinical Trial Update INMUNE BIO, INC. (INMB) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Authorization
    • Diseases/Conditions: Ebstrocel™ in RDEB, RDEB BOCA RATON
    • Clinical Stage: Phase 2
    • Collaboration: pre-Marketing Authorization Application Management Commentary: '"Definitive MHRA alignment across CMC, non-clinical and clinical strategy is an important regulatory de-risking milestone for Ebstrocel™ and for the broader CORDStrom™ platform," said David Moss'
      • planned for the UK MHRA and EU EMA in 2026

    🔬 Clinical Development Pipeline (INMUNE BIO, INC.):

    Product Type Development Stage Therapeutic Area Source
    XPro1595 Other Phase PHASE2 Mild Cognitive Impairment (MCI) ClinicalTrials.gov
    Placebo Other Phase PHASE2 COVID-19 ClinicalTrials.gov
    INB03 Other Phase PHASE2 COVID-19 ClinicalTrials.gov
    INKmune Other Phase PHASE1 Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: INMUNE BIO, INC.
    • Ticker Symbol: INMB

Search

News categories